Corporate Banner
Satellite Banner
Stem Cells, Cellular Therapy & Biobanking
>
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

New Approach to Temperature Control in Cell Therapy Clinical Trial

Published: Wednesday, April 23, 2014
Last Updated: Wednesday, April 23, 2014
Bookmark and Share
CoolCell® cell freezing device and CoolBox™ ice-free cooling workstations chosen to support handling and processing of investigational cell therapy product in landmark clinical research trial.

BioCision, LLC has announced that several of the company’s products used to support temperature control, as well as processing and handling of cell therapy products, will be used in a Phase IIb clinical trial conducted by TxCell.

The trial will investigate the use of Ovasave®, an antigen-specific regulatory T (Ag-Treg) autologous cell-based immunotherapy for the treatment of patients with moderate to severe refractory Crohn’s disease.

In the Ovasave® Phase IIb trial, TxCell, which specializes in developing cell-based therapies for chronic inflammatory disease, will use the BioCision CoolCell® passive cell freezing device as the method for freezing Ag-Treg cells.

In previous Ovasave® trials, TxCell used electronic programmable controlled-rate freezers (CRF) to manage the cell freezing temperature, however, the CoolCell® containers will be used for this trial as they provide a cost-effective alternative to the CRF, with the same freezing efficiency and post-thaw outcomes, while also being significantly less expensive to deploy and maintain.

Regulatory T cells are extremely sensitive and changes in efficacy can occur with variations in temperature and handling regimes. TxCell determined that the BioCision products are suitable for use in their authorized Class B manufacturing facility and, therefore, also chose the BioCision CoolBox™ ice-free cooling workstations to ensure standardized and reproducible handling of the cells during manufacturing. The proprietary CoolBox ice-free cooling technology enables asceptic workflow and uniform sample handling, minimizing risk of temperature fluctuation and contamination.

“BioCision products can help researchers in cellular and regenerative medicine achieve the highest possible standards in sample processing and handling, especially as it relates to standardizing the cell cryopreservation workflow,” said Rolf Ehrhardt, MD, PhD, BioCision CEO. “We are pleased that TxCell has selected BioCision products for the Ovasave® Phase IIb trial, and we look forward to working them and other leaders in regenerative medicine and cell therapy research to advance these promising therapies.”

In October 2012, TxCell has announced publication of complete results of the Phase I/II CATS1 study and presented data from a one-year extension of the study supporting the long term tolerability of Ovasave® in the treatment of patients with moderate to severe refractory Crohn’s disease. The development of Ovasave® involves a proprietary manufacturing process where Ag-Treg cells are isolated from the whole blood of the patient and are then expanded ex vivo before reinjection into that same patient.

“As we advance our promising clinical research program for Ovasave® to a Phase IIb trial, the BioCision product portfolio and technology platform present the ideal range of capabilities and quality standards necessary to help us maintain the essential levels of standardization and control we need to be successful,” said TxCell Arnaud Foussat, Vice President Research and New Products at TxCell.

TxCell will present additional details on the use of CoolCell® containers for cell freezing on April 24, 2014 during Poster Session 1 at the 20th Annual Meeting of the International Society of Cellular Therapy in Paris. The abstract is titled, “Use of a low-cost passive freezing device in the effective cryopreservation and recovery of human regulatory T-cells for use in a cell therapy trial.”

The authors evaluated CoolCell containers as an alternative to the classical controlled-rate freezer, resulting in a new standardized method of cell therapy product cryopreservation and marking an important milestone in the ultimate use of cell therapy in the clinic.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

CryoPod™ Takes Top Award at ESBB
Industry-first portable cryogenic biospecimen carrier with data logging capability receives second award for innovation.
Wednesday, October 21, 2015
BioCision Announces FDA Master File Acceptance for ThawSTAR
Submission to accelerate adoption of new point-of-care cell thawing technology.
Thursday, September 10, 2015
BioCision ThawSTAR Wins Top Honor for Innovation and Design
ThawSTAR wins gold from instrument business outlook (ibo) in the laboratory equipment industrial design category.
Thursday, August 27, 2015
BioCision to Develop Controlled-Rate Cell Freezing Systems for Cook Regentec Cell Therapy Vials
BioCision and Cook ink exclusive deal to combine technologies to standardize cell cryopreservation in closed-system vials.
Wednesday, July 29, 2015
BioCision to Collaborate with Celgene Cellular Therapeutics
Companies to collaborate on standardizing and de-risking cell thawing process for a Phase 2 cell therapy for the treatment of diabetic foot ulcers.
Wednesday, June 03, 2015
Brooks Automation, BioCision Announce Equity Investment and Strategic Collaboration
Brooks invests $4 million into BioCision to build strategic alignment in biobanking and sample handling.
Monday, March 24, 2014
BioCision Announces Two New U.S. Patents for Thermo-Conductive Products
New patents awarded for CoolSink® Plate Modules and ThermalTray™ Platforms.
Thursday, June 20, 2013
BioCision’s CoolProduct range now available from SANYO
BioCision, LLC have announced the signing of a product distribution agreement with SANYO E&E Europe BV, SANYO’s biomedical division in Europe. SANYO will be marketing the entire CoolProduct portfolio – a modular system of benchtop laboratory tools based on BioCision’s patented technology for temperature change and control of benchtop biomedical samples.
Wednesday, November 17, 2010
Scientific News
Controlling DNA Repair
Scientists discover that DNA repair outcomes following CRISPR-Cas9 cleaving are non-random and can be harnessed to produce desired effects.
Gene Therapy Via Ultrasound
Research into a gene therapy approach called sonoporation could help combat heart disease and cancer.
Stem Cell Therapy Heals Injured Mouse Brain
A team of researchers has developed a therapeutic technique that dramatically increases the production of nerve cells in mice with stroke-induced brain damage.
Challenging Stem Cell Fate Control
Researchers have found that the fate of stem cells is not only controlled by their local niche, but also by a cell-intrinsic mechanism.
Zika Proteins Responsible for Microcephaly Identified
Researchers have undertaken the first study to examine Zika infection in human neural stem cells from second-trimester fetuses.
Heart Muscle from Stem Cells Aid Cardiovascular Medicine
Researchers discover heart muscle cells from stem cells mirror expression patterns of key genes in donor tissue.
Examining New Hypotheses for Undiagnosed Patients
UnDx Consortium gathers in San Diego to create new paths to identifying currently undiagnosed illnesses.
Novel Therapeutic Approach for Blood Disorders
Gene editing of human blood-forming stem cells mimics a benign genetic condition that helps to overcome sickle cell disease and other blood disorders.
Bone Marrow Transplants Without Using Chemotherapy
Scientists have devised a way to destroy blood stem cells in mice without using chemotherapy or radiotherapy, both of which have toxic side effects.
How Cloud Connectivity Can Combat the Reproducibility Crisis
This infographic explains the reproducibility crisis, and how cloud connectivity can help overcome this problem.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!